Radiopharm - Model AVß6 - Integrin Radioactive Drugs
AVβ6 is the invention of internationally regarded integrin expert Professor Johannes Notni, formerly at the Technical University of Munich and now Professor at Essen University.
-
Most popular related searches
Products Details
- AVβ6 is a strong and selective ligand for a cell surface protein called αvβ6-integrin. As such, it can accumulate in tissue areas characterized by high αvβ6-integrin levels
- There is compelling evidence that αvβ6-Integrin is found in many of the most challenging cancers, such as pancreatic carcinoma, cervical, head-and-neck and certain lung cancers
- AVβ6 offers an unparalleled performance for radiolabelling with Gallium-68
- AVβ6 is a highly promising clinical candidate for early detection of the aforementioned conditions by PET imaging
- Radiopharm Theranositcs plans to design & synthesise a number of conjugates for a therapeutic approach and enter clinical trials at the earliest opportunity
European Journal of Nuclear Medicine and Molecular Imaging – Image of the Month
- αvβ6-specific peptide
- PET/CT image of primary tumour in pancreatic head
- Pancreatic ductal carcinoma confirmed histologically
- Prominent signals are observed only in kidneys and urinary bladder due to renal excretion
- No relevant uptake is seen in lungs, stomach, liver and intestines
- Potential applications for fibrosis, PDAC and other carcinomas (head-and-neck squamous cell, lung adenocarcinoma, colon, cervical, mammary)
Customer reviews
No reviews were found for Radiopharm - Model AVß6 - Integrin Radioactive Drugs. Be the first to review!